Becker's Healthcare December 7, 2022
Noah Schwartz

Syndax, a biopharmaceutical company focusing on cancer therapies, has announced the pricing of a $150 million public offering of common stock.

The offering price is $22 for each share of 6,818,182 shares of stock. Additionally, the company...

Today's Sponsors

Transcarent
SalesSparx

Today's Sponsor

Health Edge

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Amazon’s RxPass Doesn’t Yet Really Compete With Mark Cuban’s Cost Plus Drug Company
Pfizer and Ada Health Inc. To Launch Nationwide Online COVID-19 Care Journey
2023’s Biggest Pharma Cybersecurity Threats to Watch

Share This Article